Cite

HARVARD Citation

    Blauvelt, A. et al. (2018). Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials. British journal of dermatology. pp. 615-622. [Online]. 
  
Back to record